Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study.
NCT ID: NCT06314139
Last Updated: 2024-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-09-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Continuous theta burst stimulation (cTBS) is one of the non-invasive electrophysiological techniques characterized by plexus stimulation, which is similar to low-frequency repetitive transcranial magnetic stimulation (rTMS) but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. The stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. In addition, functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique. It mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm. The efficacy, safety, and mechanisms involved in non-invasive stimulation therapy for ET patients are still unclear. There are few studies on the treatment of ET with cTBS, and the sample size is small (the largest sample includes only 23 ET patients). Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, the investigators conducted a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor
NCT01334814
Long Term Efficacy and Safety of TMS Targeting Cerebellum to Treat DRE
NCT06832813
The Mechanism of cTBS Targeting Dentate Nucleus for DRE
NCT05809349
cTBS Targeting Cerebellum for Drug-refractory Epilepsy
NCT05042726
Neuromodulation Strategies for Treatment-Resistant Essential Tremor Using Chronos™ DBS
NCT07302867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The pathology of the disease is not yet clear, it is generally believed that genetic, aging and environmental factors are related to ET. Hyperactivity of cerebellar function and changes of cerebello-thalamo- cortical (CTC) pathways are currently considered to be the most important pathophysiological mechanisms of ET. The degenerative changes of cerebellum in ET patients are prominent, such as the loss of Purkinje cells and focal axonal swelling. In addition, imaging, electrophysiological studies and clinical observations show that the cerebral cortex may also be involved. Studies have shown that the activity of cortical area is related to the frequency of tremor, and there have been reports on the disappearance of ET after cortical infarction. Therefore, the cerebellum and cortex may be the best targets for the treatment of tremor.
Transcranial magnetic stimulation (TMS) is a non-invasive electrophysiological technique for nerve stimulation and nerve regulation invented by Anthony Barker in 1985. Its principle is to use electromagnetic fields to generate induced electric fields in the brain, change abnormal brain waves of patients, and regulate the secretion of neurotransmitters and hormones closely related to emotion, cognition, sleep and other functions in the brain, so as to achieve the therapeutic effect. Continuous theta burst stimulation (cTBS) is characterized by plexus stimulation, which is similar to low-frequency rTMS but closer to the physiological state of neural activity, and may inhibit the excitability of the stimulated cortex. Moreover, the intervention time of CTBS is only 40 seconds, the stimulation intensity is lower, and the stimulation duration is greatly shortened, which is simpler and easier than the low-frequency rTMS of 20-30 minutes. The investigators hypothesized that CTBS would reduce the excitability of cerebellar cortex, thereby reducing the amplitude of tremor, and play a therapeutic role in ET patients.
Functional near infrared spectroscopy (fNIRS) is a new non-invasive functional neuroimaging technique in recent years. fNIRS mainly uses the difference characteristics of oxyhemoglobin and deoxyhemoglobin in brain tissue for near-infrared light absorption at different wavelengths of 600-900nm to directly detect the hemodynamic activities of cerebral cortex in real time, and then through observing such hemodynamic changes, discover the neurovascular coupling law, so as to deduce the neural activities of the brain. In the past 20 years, the hardware manufacturing and improvement of functional near-infrared spectroscopy technology and data processing methods have become more and more perfect, making the fNIRS technology, which uses near-infrared light to observe brain neural activities, to study various cognitive activities emerge in endlessly and develop rapidly. fNIRS is based on light intensity. Optical imaging equipment has high cost performance and is not vulnerable to electromagnetic interference from TMS pulses. It can conduct more detailed research on cortical connectivity, excitability and dynamic changes induced by cTBS.
Studies by Chuang et al. showed that after the treatment of cTBS over motor cortex or premotor cortex, the tremor amplitude of ET patients decreased significantly, but the tremor frequency remained unchanged. Hellriegel et al. included 10 ET patients and 10 healthy controls. They performed a single cTBS treatment on the primary motor cortex of the patients. They found that compared with the control group, the cTBS group reduced the total power of tremor assessed by the accelerometer, but this beneficial effect was subclinical, that is, the tremor assessment of the patients had no significant change before and after treatment. Bologna et al. included 16 ET patients and 11 healthy controls. They were treated with cTBS and sham stimulation in the right cerebellar hemisphere with crossing over after a one-week washout period. The results showed that the tremor was not significantly improved before and after CTBS treatment. They also pointed out that multiple stimuli may be effective. However, there is a lack of research on the therapeutic mechanism of cTBS in the treatment of ET. The combination of transcranial magnetic stimulation (TMS) and neuroimaging provides a new way to explore the mechanisms involved. High frequency rTMS could improve mild cognitive impairment after stroke and increase the concentration of oxyhemoglobin in prefrontal lobe. Study have observed the changes of activation mode of cerebral cortex during upper limb movement in stroke patients before and after repeated transcranial magnetic stimulation (rTMS) treatment through near infrared brain functional imaging (fNIRS). Struckmann et al. used fNIRS technology to compare the changes of prefrontal blood oxygen response in patients with depression before and after intermittent TBS treatment. They also confirmed that the oxygen and hemoglobin of patients did change before and after treatment, and further discussed the mechanism.
To sum up, there are few domestic and international clinical studies on the treatment of ET with CTBS, and the sample size is small (the largest sample includes only 23 ET patients). The results showed that the placebo effect was strong, and all of them were stimulated by single site, and the effect was not significant. Additionally, there was a lack of exploration on the therapeutic mechanism of cTBS for ET patients. Therefore, The investigators will conduct a double-blind, randomized, sham-controlled clinical trial to evaluate the safety and efficacy of cTBS in the treatment of ET patients over both cerebellar and cortical area. fNIRS technology will be applied to provide new ideas for the pathophysiological mechanism and treatment of ET.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cTBS group
cTBS at 80% action motor threshold (AMT) with 600 pulses over bilateral M1 and cerebellum. Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum.
continuous theta-burst stimulation (cTBS)
Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
sham group
Sham stimulation was performed with the same protocol using an inactive coil to mimic true stimulation sound effects, but does not stimulate the brain or produce neurophysiological changes in cerebello-thalamo-cortical (CTC) connections and eyeblink regulation.
continuous theta-burst stimulation (cTBS)
Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continuous theta-burst stimulation (cTBS)
Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-hand dominant
* Were willing to participate in the trial and signed informed consent
* Essential tremor Diagnosis based on the International Parkinson and Movement Disorder Society (IPMDS) ET diagnostic criteria in 2017
Exclusion Criteria
* Combined with other central nervous system diseases except ET
* drug or alcohol withdrawal-induced tremor, psychogenic/physiological/orthostatic/task-specific tremor
* Contraindications for undergoing cTBS, such as epilepsy history, intracranial metal implants, pacemaker installers, etc
* Skin lesions at stimulation sites
* Pregnant or breastfeeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanming Xu
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xu Yanming
Role: STUDY_DIRECTOR
Department of Neurology, West China Hospital, Sichuan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurology, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan Province 610041, P.R. China.
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YanmingXu001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.